Boehringer submits Pradaxa antidote app; Sanofi's Lantus follow-up nears EMA approval;

> Boehringer Ingelheim has submitted an FDA application for its Pradaxa antidote. Release | More

> The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi's ($SNY) Lantus follow-up, Toujeo, for European approval. Report

> India's Natco Pharma is challenging the patent on Gilead's Sovaldi despite its licensing agreement to make and sell cheap versions of the drug. More (sub. req.)

> AstraZeneca ($AZN) has completed its deal for Actavis' ($ACT) North American respiratory portfolio. Brief

And Finally... Millennials aren't big on big purchases--even cars and houses--but they do like to spend money on health and fitness gadgets. Infographic

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.